IP Library Granted Patent US 9,856,251
Granted Patent B2
US 9,856,251 · App. 15/235,312 · Granted Jan 2, 2018

Substituted berbines and processes for their synthesis

Inventors: Peter X. Wang (Clarkson Valley, MO); Frank W. Moser (Arnold, MO); Gary L. Cantrell (Troy, IL); Christopher W. Grote (Webster Groves, MO)
Assignee: Mallinckrodt LLC
C07D455/03B01J31/2295C07D217/20B01J2231/643B01J2531/821
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,856,251
App. No.
15/235,312
Granted
Jan 2, 2018
Kind
B2
Abstract

The present invention provides processes for the synthesis of substituted berbine compounds. Also provided are intermediates used in the synthesis of substituted berbine compounds.

Claims (19)

1. A process for preparing compound 9, the process comprising forming a reaction mixture in which compound 6 is contacted with dichloro-(p-cymene)-Ru(II) dimer and formic acid-triethylamine to form compound 7, and adding RCHO to the reaction mixture to form compound 9 according to the following reaction scheme:

wherein:

R is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, halogen, OR 13 , hydrocarbyl, substituted hydrocarbyl, and together R 2 and R 3 form {—}O(CH 2 ) n O{—};

R 5 , R 6 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, halogen, OR 13 , hydrocarbyl, substituted hydrocarbyl, and together R 6 and R 7 form {—}O(CH 2 ) n O{—};

R 9 , R 10 , R 11 , and R 12 are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 13 is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl; and

n is an integer from 1 to 3.

2. The process of claim 1 , wherein R is selected from the group consisting of alkyl, substituted alkyl, aryl, and substituted aryl, and R 13 is alkyl.

3. The process of claim 1 , wherein each of R 9 , R 10 , R 11 , and R 12 is hydrogen.

4. The process of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, OR 13 , and together R 2 and R 3 form {—}O(CH 2 ) n O{—}; and R 5 , R 6 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, OR 13 , and together R 6 and R 7 form {—}O(CH 2 ) n O{—}; wherein R 13 is hydrogen or an alkyl having 1 to 8 carbon atoms, and n is 1 to 3.

5. The process of claim 1 , wherein compound 7 and RCHO are present at a molar ratio of about 1:0.5 to about 1:2.

6. The process of claim 1 , wherein the reaction is conducted in the presence of a solvent selected from the group consisting of acetone, acetonitrile, butanone, chloroform, 1,2,-dichloroethane, dichloromethane, ethyl acetate, n-propyl acetate, isopropyl acetate, methanol, methyl t-butyl ether, methyl butyl ketone, tetrahydrofuran, toluene, and combinations thereof.

7. The process of claim 1 , wherein the reaction is conducted is conducted at a temperature ranging from about 00° C. to about 120° C.

8. The process of claim 1 , wherein compound 9 has a yield of at least about 80%.

9. The process of claim 1 , wherein R is alkyl; R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, OR 13 , and together R 2 and R 3 form {—}O(CH 2 )O{—}; R 5 , R 6 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, OR 13 , and together R 6 and R 7 form {—}O(CH 2 )O{—}; and each of R 9 , R 10 , R 11 , and R 12 is hydrogen, wherein R 13 is hydrogen or methyl.

10. The process of claim 9 , wherein the reaction is conducted in the presence of a solvent selected from the group consisting of acetonitrile, chloroform, methanol, and combinations thereof.

11. The process of claim 10 wherein the reaction is conducted is conducted at a temperature ranging from about 10° C. to about 80° C.

12. The process of claim 11 , wherein compound 9 has a yield of about 80% to about 99.9%.

Assignments (14)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2025
From: WANG, PETER X.; MOSER, FRANK W.; CANTRELL, GARY L.; GROTE, CHRISTOPHER W.
To: MALLINCKRODT INC.
Reel/Frame 073336/0024 →
CHANGE OF NAME Recorded Dec 30, 2025
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 074136/0302 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0124 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0375 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0124 →
Continuity (3)
Continuation 12552457 · Sep 2, 2009
Provisional Application 61093820 · Sep 3, 2008
Related Publication 20160347747A1 · Dec 1, 2016